儿童青少年及青年女性癌症幸存者乳腺癌监测建议更新
国际儿童癌症晚期效应指南协调组基于新证据更新了儿童、青少年及青年女性癌症幸存者的乳腺癌监测建议。更新涉及中等剂量胸部放疗(10-19 Gy)、蒽环类和烷化剂暴露及卵巢功能对乳腺癌风险的影响,并修订了乳腺X线和磁共振的监测推荐。
要点
- 胸部放疗≥10 Gy的幸存者建议每年进行乳腺X线和乳腺磁共振监测至60岁(强推荐)。
- 年轻时期上腹部放疗暴露乳腺组织者建议每年监测至60岁(中等推荐)。
- 无胸部放疗的蒽环类暴露幸存者,因证据不一致无法制定常规乳腺癌监测推荐。
核心结论
- 新证据促使对2013年建议中关于中等剂量胸部放疗、蒽环类暴露及乳腺癌监测方式的内容进行重大修改。
研究设计与样本
- 指南制定机构为国际儿童癌症晚期效应指南协调组,采用循证方法更新2013年国际协调建议。
- 指南小组更新系统文献综述、制定证据总结、评价证据,并使用GRADE证据至决策框架将证据转化为推荐。
主要发现
- 文献更新识别了关于处方中等剂量胸部放疗(10-19 Gy)、放疗剂量-体积、无胸部放疗幸存者中蒽环类和烷化剂效应以及卵巢功能对乳腺癌风险影响的新研究结果。
- 来自霍奇金淋巴瘤幸存者的前瞻性研究提供了乳腺X线和磁共振成像性能指标的新数据。
关键数值与推荐
- 对于接受胸部放疗≥10 Gy的幸存者,建议每年进行乳腺X线和乳腺磁共振成像监测至60岁(强推荐)。
- 对于年轻时期上腹部放疗暴露乳腺组织的幸存者,建议每年进行乳腺X线和乳腺磁共振成像监测至60岁(中等推荐)。
- 对于无胸部放疗的任何类型蒽环类暴露幸存者,因证据不一致,无法制定常规乳腺癌监测推荐。
临床怎么用
- 对胸部放疗≥10 Gy或年轻时期上腹部放疗暴露乳腺组织的女性幸存者,应每年进行乳腺X线和乳腺磁共振监测至60岁。
- 对无胸部放疗的蒽环类暴露幸存者,目前无法给出常规乳腺癌监测推荐,需个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As new evidence is available, the International Late Effects of Childhood Cancer Guideline Harmonization Group has updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer. METHODS: We used evidence-based methods to apply new knowledge in refining the international harmonized recommendations developed in 2013. The guideline panel updated the systematic literature review, developed evidence summaries, appraised the evidence, and updated recommendations on the basis of evidence, clinical judgement, and consideration of benefits versus the harms of the surveillance interventions while attaining flexibility in implementation across different health care systems. The GRADE Evidence-to-Decision framework was used to translate evidence to recommendations. A survivor information form was developed to counsel survivors about the potential harms and benefits of surveillance. RESULTS: The literature update identified new study findings related to the effects of prescribed moderate-dose chest radiation (10 to 19 Gy), radiation dose-volume, anthracyclines and alkylating agents in non-chest irradiated survivors, and the effects of ovarian function on breast cancer risk. Moreover, new data from prospective investigations were available regarding the performance metrics of mammography and magnetic resonance imaging among survivors of Hodgkin lymphoma. Modified recommendations include the performance of mammography and breast magnetic resonance imaging for survivors treated with 10 Gy or greater chest radiation (strong recommendation) and upper abdominal radiation exposing breast tissue at a young age (moderate recommendation) at least annually up to age 60 years. As a result of inconsistent evidence, no recommendation could be formulated for routine breast cancer surveillance for survivors treated with any type of anthracyclines in the absence of chest radiation. CONCLUSION: The newly identified evidence prompted significant change to the recommendations formulated in 2013 related to moderate-dose chest radiation and anthracycline exposure as well as breast cancer surveillance modality.
引用
- Mulder RL, Hudson MM, Bhatia S, et al. Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. J Clin Oncol. 2020. PMID: 33078972. doi:10.1200/JCO.20.00562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。